Evinature
Clinically proven, evidence-based nutraceuticals for gut health tailored to IBD, IBS, diverticulitis
StartupEvinature is a Binyamina-Giv'at Ada-based startup in the Health Tech & Life Sciences sector, established in 2021. Clinically proven, evidence-based nutraceuticals for gut health tailored to IBD, IBS, diverticulitis. The company has raised a total of $6.5M across 3 funding rounds, currently at the Seed stage. Evinature was founded by Apan Amos Damri, Dr. Prof. Shomron Ben-Horin M.D., Nir Salomon ChB. The company has 11-50 employees. Core technologies: Biologicals, Herbals.
With $6.5M in total funding, Evinature is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B/B2B2C/B2C business model. Product stage: Released. The company holds 1 patent.
- StageSeed
- ProductReleased
- ModelB2B, B2B2C, B2C
- Employees11-50
- HQBinyamina-Giv'at Ada
- Last Round$2.5M
Apan Amos DamriFounder, CEODr. Prof. Shomron Ben-Horin M.D.Founder, Chief Medical Officer
Nir Salomon ChBFounder, Head of R&D
38 articles covered by sources including evinature.com,
www.frontiersin.org,
thesanfranciscotribune.com,
worldfinancialreview.com,
ritzherald.com.
What does Evinature do?
Evinature was founded on the nexus of two medical philosophies. By bridging the gap between modern and traditional medicine, we’re able to provide more patients with safe and natural remedies that are embraced by the medical community. We believe it’s time for healthcare to prioritize patient global accessibility to accurate medical assessments and affordable treatments. No patents, no trends, no misinformation. We simply develop, test, prove, then give back to the community. Tailored Protocols: No two bodies are the same, which is why we provide evidence-based protocols that address each patient’s condition and state of severity so we can precisely target your individual needs and improve long-term results. Guided Care: Regular online follow-ups enable precise adjustments to your protocol so we can address your changing needs throughout treatment. And to ease the way, we also provide complementary clinic support to guide you through the entire process. Labs: We’re constantly refining our products through ongoing research and collaborations with over 20 leading medical centers in the U.S, enabling the further development of effective neutraceuticals that are accessible to patients worldwide. Evidence: Evinature prioritizes evidence above the trends. We are caregivers by profession, and therefore emphasize product quality and scientific integrity above all else, exclusively distributing products that have passed the golden standard of clinical trials. By the Patient for the Patient: Patients are the greatest untapped resource in healthcare, which is why we’ve developed a research database founded on their invaluable experience. At Evinature, each patient contributes to the community simply by taking the assessment. This allows us to constantly expand our research and keep the community updated with vital news and information.
How much funding has Evinature raised?
Evinature has raised $6.5M in total funding across 3 rounds. The company is currently at the Seed stage.
Who founded Evinature?
Evinature was founded in 2021 by Apan Amos Damri (Founder, CEO), Dr. Prof. Shomron Ben-Horin M.D. (Founder, Chief Medical Officer), Nir Salomon ChB (Founder, Head of R&D).
What sector is Evinature in?
Evinature operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Herbals. Target customers: Healthcare & Life Sciences, Healthcare, Patients.
Where is Evinature located?
Evinature is based in HaMelacha St 3, Binyamina-Giv'at Ada, Israel.